FMP
Akari Therapeutics, Plc
AKTX
NASDAQ
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
1.19 USD
-0.03 (-2.52%)
About
ceo
Ms. Rachelle Suzanne Jacques
sector
Healthcare
industry
Biotechnology
website
https://www.akaritx.com
exchange
NASDAQ
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
CIK
0001541157
ISIN
US00972G2075
CUSIP
00972G108
Address
75/76 Wimpole Street
Phone
44 20 8004 0270
Country
GB
Employee
9
IPO Date
Jan 6, 2014
Key Executives
